Prediction of the response to chemotherapy in advanced esophageal cancer by gene expression profiling of biopsy samples

International Journal of Oncology

Volumn 37, Issue 5, 2010, Pages 1113-1120

  Motoori, Masaaki ^a,b   Takemasa, Ichiro ^a   Yamasaki, Makoto ^a   Komori, Takamichi ^a   Takeno, Atsushi ^a   Miyata, Hiroshi ^a   Takiguchi, Shuji ^a   Fujiwara, Yoshiyuki ^a   Yasuda, Takushi ^a   Yano, Masahiko ^b   Matsuura, Nariaki ^a   Matsubara, Kenichi ^c   Monden, Morito ^a   Mori, Masaki ^a   Doki, Yuichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c DNA CHIP RESEARCH INC   (Japan)

Author keywords

Biopsy sample; Chemosensitivity; Esophageal cancer; Gene expression profiling

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS BIOPSY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 77957885901     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000763     Document Type: Article

References (31)

1. Akiyama H, Tsurumaru M, Udagawa H and Kajiyama Y: Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 220: 364-372, 1994. (Pubitemid 24313229)
2. Medical Research Council Oesophageal Cancer Working Group: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359: 1727-1733, 2002.
3. Kelsen DP, Ginsberg R, Pajak TF, et al: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339: 1979-1984, 1998.
4. Shimada Y, Watanabe G, Yamasaki S, et al: Histological response of cisplatin predicts patients' survival in oesophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity. Eur J Cancer 36: 987-993, 2000.
5. Miyata H, Doki Y, Shiozaki H, et al: CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. Clin Cancer Res 6: 4859-4865, 2000.
6. Kishi K, Doki Y, Miyata H, Yano M, Yasuda T and Monden M: Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer. Br J Surg 89: 597-603, 2002. (Pubitemid 34415610)
7. Langer R, Specht K, Becker K, et al: Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin Cancer Res 11: 7462-7469, 2005.
8. Ponder BAJ: Cancer genetics. Nature 411: 336-341, 2001.
9. Ramaswamy S and Golub TR: DNA microarrays in clinical oncology. J Clin Oncol 20: 1932-1941, 2002.
10. Golub TR, Slonim DK, Tamayo P, et al: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537, 1999.
11. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536, 2002.
12. Beer DG, Kardia SL, Huang CC, et al: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8: 816-824, 2002.
13. Iizuka N, Oka M, Yamada-Okabe H, et al: Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 361: 923-929, 2003. (Pubitemid 36332108)
14. Motoori M, Takemasa I, Yano M, et al: Prediction of recurrence in advanced gastric cancer patients after curative resection by gene expression profiling. Int J Cancer 14: 963-968, 2005. (Pubitemid 40504478)
15. Ayers M, Symmans WF, Stec J, et al: Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22: 2284-2293, 2004. (Pubitemid 41115384)
16. Clarke PA, George ML, Easdale S, et al: Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling. Cancer Res 63: 6855-6863, 2003. (Pubitemid 37322968)
17. Luthra R, Wu TT, Luthra MG, et al: Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol 24: 259-267, 2006. (Pubitemid 46628468)
18. Komori T, Takemasa I, Yamasaki M, et al: Gene expression of colorectal cancer: preoperative genetic diagnosis using endoscopic biopsies. Int J Oncol 32: 367-375, 2008. (Pubitemid 351188303)
19. Motoori M, Takemasa I, Yamasaki M, et al: The feasibility of using biopsy samples from esophageal cancer for comprehensive gene expression profiling. Int J Oncol 35: 265-271, 2009.
20. Akita H, Doki Y, Miyata H, et al: Clinical significance of the second cycle response to cisplatin-based chemotherapy as preoperative treatment for esophageal squamous cell carcinoma. J Surg Oncol 93: 401-409, 2006.
21. Matsuyama J, Doki Y, Yasuda T, et al: The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus. Surgery 141: 570-580, 2007.
22. Weber WA, Ott K, Becker K, et al: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19: 3058-3065, 2001.
23. Wieder HA, Brücher BL, Zimmermann F, et al: Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22: 900-908, 2004.
24. Levine EA, Farmer MR, Clark P, et al: Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg 243: 472-478, 2006.
25. Duong C, Greenawalt DM, Kowalczyk A, et al: Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer. Ann Surg Oncol 14: 3602-3609, 2007.
26. Darnton SJ, Archer VR, Stocken DD, Mulholland PJ, Casson AG and Ferry DR: Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival. J Clin Oncol 21: 4009-4015, 2003.
27. Law S, Fok M, Chow S, Chu KM and Wong J: Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 114: 210-217, 1997.
28. Ihrie RA, Reczek E, Horner JS, Khachatrian L, Sage J, Jacks T and Attardi LD: Perp is a mediator of p53-dependent apoptosis in diverse cell types. Curr Biol 13: 1985-1990, 2003.
29. Castagna A, Antonioli P, Astner H, et al: A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 4: 3246-3267, 2004.
30. Chai J, Baatar D and Tarnawski A: Serum response factor promotes re-epithelialization and muscular structure restoration during gastric ulcer healing. Gastroenterology 126: 1809-1818, 2004.
31. Tanaka K, Kondoh N, Shuda M, et al: Enhanced expression of mRNAs of antisecretory factor-1, gp96, DAD1 and CDC34 in human hepatocellular carcinomas. Biochim Biophys Acta 1536: 1-12, 2001.